WO2005118833A3 - Diagnostics and therapeutics for diseases associated with sterile-alpha motif and leucine zipper containing kinase (zak) - Google Patents

Diagnostics and therapeutics for diseases associated with sterile-alpha motif and leucine zipper containing kinase (zak) Download PDF

Info

Publication number
WO2005118833A3
WO2005118833A3 PCT/EP2005/005436 EP2005005436W WO2005118833A3 WO 2005118833 A3 WO2005118833 A3 WO 2005118833A3 EP 2005005436 W EP2005005436 W EP 2005005436W WO 2005118833 A3 WO2005118833 A3 WO 2005118833A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
zak
therapeutics
diagnostics
sterile
Prior art date
Application number
PCT/EP2005/005436
Other languages
French (fr)
Other versions
WO2005118833A2 (en
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Andreas Geerts filed Critical Bayer Healthcare Ag
Publication of WO2005118833A2 publication Critical patent/WO2005118833A2/en
Publication of WO2005118833A3 publication Critical patent/WO2005118833A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases

Abstract

The invention provides a human ZAK which is associated with cardiovascular diseases, dermatological diseases, endocrinological diseases, metabolic diseases, cancer, (thyroid, esophagus, stomach, colon, ovary, protate tumor) inflammation, gastroenterological diseases, (e.g. liver virrhosis) hematological diseases, respiratory diseases, muscle skeleton diseases, neurological diseases and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, dermatological diseases, endocrinological diseases, metabolic diseases, cancer, inflammation, gastroenterological diseases, hematological diseases, respiratory diseases, muscle skeleton diseases, neurological diseases and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of ZAK as well as pharmaceutical compositions comprising such compounds.
PCT/EP2005/005436 2004-06-01 2005-05-19 Diagnostics and therapeutics for diseases associated with sterile-alpha motif and leucine zipper containing kinase (zak) WO2005118833A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04012873 2004-06-01
EP04012873.8 2004-06-01

Publications (2)

Publication Number Publication Date
WO2005118833A2 WO2005118833A2 (en) 2005-12-15
WO2005118833A3 true WO2005118833A3 (en) 2006-05-11

Family

ID=35004289

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/005436 WO2005118833A2 (en) 2004-06-01 2005-05-19 Diagnostics and therapeutics for diseases associated with sterile-alpha motif and leucine zipper containing kinase (zak)

Country Status (1)

Country Link
WO (1) WO2005118833A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102341102A (en) * 2009-03-06 2012-02-01 诺瓦提斯公司 Use of pyrimidylaminobenzamide derivatives for treatment of disorders mediated by leucine zipper- and sterile alpha motif-containing kinase (zak)
WO2011050319A2 (en) * 2009-10-23 2011-04-28 Oregon Health & Science University Inhibiting the deleterious effect of anthracyclines
EP3033625B1 (en) * 2013-08-13 2020-01-22 The Scripps Research Institute Cysteine-reactive ligand discovery in proteomes
JP6953400B2 (en) 2015-10-22 2021-10-27 ザ スクリプス リサーチ インスティテュート Cysteine-reactive probe and its use
CA3050260A1 (en) 2017-01-18 2018-07-26 The Scripps Research Institute Photoreactive ligands and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6183962B1 (en) * 1998-09-09 2001-02-06 Millennium Pharmaceuticals, Inc. Protein kinase molecules and uses therefor
WO2003048359A1 (en) * 2001-12-05 2003-06-12 Sumitomo Pharmaceuticals Company, Limited Markers for sugar/lipid metabolic disorders and utilization thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6183962B1 (en) * 1998-09-09 2001-02-06 Millennium Pharmaceuticals, Inc. Protein kinase molecules and uses therefor
WO2003048359A1 (en) * 2001-12-05 2003-06-12 Sumitomo Pharmaceuticals Company, Limited Markers for sugar/lipid metabolic disorders and utilization thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LIU T-C ET AL: "Cloning and expression of ZAK, a mixed-lineage kinase-like protein containing a leucine-zipper and a sterile-alpha motif", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 274, 11 August 2000 (2000-08-11), pages 811 - 816, XP002167497, ISSN: 0006-291X *

Also Published As

Publication number Publication date
WO2005118833A2 (en) 2005-12-15

Similar Documents

Publication Publication Date Title
WO2006027147A3 (en) Diagnostics and therapeutics for diseases associated with adrenomedullin receptor (amdr)
WO2005093092A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 44 (gpr44)
WO2006010517A3 (en) Diagnostics and therapeutics for diseases associated with fibroblast activation protein (fap)
WO2005106012A3 (en) Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 1 (dpp1)
WO2005118833A3 (en) Diagnostics and therapeutics for diseases associated with sterile-alpha motif and leucine zipper containing kinase (zak)
WO2006005469A3 (en) Diagnostics and therapeutics for diseases associated with glucagon receptor (gcgr)
WO2005106491A3 (en) Diagnostics and therapeutics for diseases associated with serum/glucocorticoid regulated kinase 1 (sgk1)
WO2006010514A3 (en) Diagnostics and therapeutics for diseases associated with dual specificity mitogen-activated protein kinase kinase 5 (map2k5)
WO2005076007A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor p2y12 (p2y12)
WO2005090994A3 (en) Diagnostics and therapeutics for diseases associated with protein kinase, cgmp-dependent, type i (prkg1)
WO2006008003A3 (en) Diagnostics and therapeutics for diseases associated with vasoactive intestinal peptide receptor 1 (vpac1)
WO2006040047A3 (en) Diagnostics and therapeutics for diseases associated with rho/rac-interacting citron kinase (cit)
WO2005106486A3 (en) Diagnostic and therapeutics for diseases associated with dipeptidyl-peptidase 3(dpp3)
WO2005073729A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor p2y11 (p2y11)
WO2005076003A3 (en) Diagnostics and therapeutics for diseases associated with plasma glutamate carboxypeptidase (pgcp)
WO2005085469A3 (en) Diagnostics and therapeutics for diseases associated with rho-associated protein kinase 1 (rock1)
WO2006013014A3 (en) Diagnostics and therapeutics for diseases associated with prostate-specific membrane antigen-like protein (psmal)
WO2005113788A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor kinase 6 (grk6)
WO2006013013A3 (en) Diagnostics and therapeutics for diseases associated with protective protein for beta-galactosidase (ppgb)
WO2004099248A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor agtr2 (agtr2)
WO2005119263A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 92 (gpr92)
WO2004104595A3 (en) Diagnostics and therapeutics for diseases associated with x-pro dipeptidase (pepd)
WO2005095631A3 (en) Diagnostics and therapeutics for diseases associated with mixed lineage kinase 4 alpha (mlk4 alpha)
WO2005114209A3 (en) Diagnostics and therapeutics for diseases associated with g protein-dependent receptor kinase 2 (grk2)
WO2006005461A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 27 (gpr27)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase